vs
Side-by-side financial comparison of Baxter International (BAX) and TE Connectivity (TEL). Click either name above to swap in a different company.
TE Connectivity is the larger business by last-quarter revenue ($4.7B vs $3.0B, roughly 1.6× Baxter International). TE Connectivity runs the higher net margin — 16.1% vs -37.9%, a 54.0% gap on every dollar of revenue. On growth, Baxter International posted the faster year-over-year revenue change (458.0% vs 21.7%). Over the past eight quarters, TE Connectivity's revenue compounded faster (8.5% CAGR vs -9.0%).
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
TE Connectivity plc is an American-Irish domiciled technology company that designs and manufactures electrical and electronic components. It serves several industries, including automotive, aerospace, defense, medical, and energy.
BAX vs TEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.0B | $4.7B |
| Net Profit | $-1.1B | $750.0M |
| Gross Margin | 19.4% | 37.2% |
| Operating Margin | -24.5% | 20.6% |
| Net Margin | -37.9% | 16.1% |
| Revenue YoY | 458.0% | 21.7% |
| Net Profit YoY | -120.3% | 42.0% |
| EPS (diluted) | $-2.21 | $2.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.0B | $4.7B | ||
| Q3 25 | $2.8B | $4.7B | ||
| Q2 25 | $2.8B | $4.5B | ||
| Q1 25 | $2.6B | $4.1B | ||
| Q4 24 | $533.0M | $3.8B | ||
| Q3 24 | $2.7B | $4.1B | ||
| Q2 24 | $3.8B | $4.0B | ||
| Q1 24 | $3.6B | $4.0B |
| Q4 25 | $-1.1B | $750.0M | ||
| Q3 25 | $-46.0M | $663.0M | ||
| Q2 25 | $91.0M | $638.0M | ||
| Q1 25 | $126.0M | $13.0M | ||
| Q4 24 | $-512.0M | $528.0M | ||
| Q3 24 | $140.0M | $276.0M | ||
| Q2 24 | $-314.0M | $573.0M | ||
| Q1 24 | $37.0M | $541.0M |
| Q4 25 | 19.4% | 37.2% | ||
| Q3 25 | 33.5% | 35.0% | ||
| Q2 25 | 35.3% | 35.3% | ||
| Q1 25 | 32.8% | 35.2% | ||
| Q4 24 | 25.0% | 35.5% | ||
| Q3 24 | 38.3% | 34.0% | ||
| Q2 24 | 37.5% | 34.8% | ||
| Q1 24 | 38.6% | 34.4% |
| Q4 25 | -24.5% | 20.6% | ||
| Q3 25 | 6.1% | 19.3% | ||
| Q2 25 | 6.8% | 18.9% | ||
| Q1 25 | 2.2% | 18.1% | ||
| Q4 24 | -25.5% | 18.0% | ||
| Q3 24 | 5.7% | 16.0% | ||
| Q2 24 | -5.0% | 19.0% | ||
| Q1 24 | 5.2% | 17.4% |
| Q4 25 | -37.9% | 16.1% | ||
| Q3 25 | -1.6% | 14.0% | ||
| Q2 25 | 3.2% | 14.1% | ||
| Q1 25 | 4.8% | 0.3% | ||
| Q4 24 | -96.1% | 13.8% | ||
| Q3 24 | 5.2% | 6.8% | ||
| Q2 24 | -8.2% | 14.4% | ||
| Q1 24 | 1.0% | 13.6% |
| Q4 25 | $-2.21 | $2.53 | ||
| Q3 25 | $-0.09 | $2.23 | ||
| Q2 25 | $0.18 | $2.14 | ||
| Q1 25 | $0.25 | $0.04 | ||
| Q4 24 | $-0.99 | $1.75 | ||
| Q3 24 | $0.27 | $0.96 | ||
| Q2 24 | $-0.62 | $1.86 | ||
| Q1 24 | $0.07 | $1.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | $1.3B |
| Total DebtLower is stronger | $9.5B | — |
| Stockholders' EquityBook value | $6.1B | $13.0B |
| Total Assets | $20.1B | $25.6B |
| Debt / EquityLower = less leverage | 1.55× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0B | $1.3B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.7B | $672.0M | ||
| Q1 25 | $2.3B | $2.6B | ||
| Q4 24 | $1.8B | $1.3B | ||
| Q3 24 | $1.4B | $1.3B | ||
| Q2 24 | $2.1B | $1.5B | ||
| Q1 24 | $3.0B | $1.2B |
| Q4 25 | $9.5B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.4B | — | ||
| Q3 24 | $10.4B | — | ||
| Q2 24 | $10.4B | — | ||
| Q1 24 | $11.1B | — |
| Q4 25 | $6.1B | $13.0B | ||
| Q3 25 | $7.2B | $12.6B | ||
| Q2 25 | $7.3B | $12.4B | ||
| Q1 25 | $7.1B | $12.1B | ||
| Q4 24 | $7.0B | $12.4B | ||
| Q3 24 | $7.9B | $12.4B | ||
| Q2 24 | $7.6B | $12.6B | ||
| Q1 24 | $8.2B | $12.4B |
| Q4 25 | $20.1B | $25.6B | ||
| Q3 25 | $21.1B | $25.1B | ||
| Q2 25 | $21.0B | $24.9B | ||
| Q1 25 | $21.3B | $23.7B | ||
| Q4 24 | $25.8B | $22.4B | ||
| Q3 24 | $26.7B | $22.9B | ||
| Q2 24 | $26.3B | $22.9B | ||
| Q1 24 | $27.8B | $22.8B |
| Q4 25 | 1.55× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 1.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $584.0M | $865.0M |
| Free Cash FlowOCF − Capex | — | $607.0M |
| FCF MarginFCF / Revenue | — | 13.0% |
| Capex IntensityCapex / Revenue | — | 5.5% |
| Cash ConversionOCF / Net Profit | — | 1.15× |
| TTM Free Cash FlowTrailing 4 quarters | — | $3.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $584.0M | $865.0M | ||
| Q3 25 | $237.0M | $1.4B | ||
| Q2 25 | $217.0M | $1.2B | ||
| Q1 25 | $-193.0M | $653.0M | ||
| Q4 24 | $488.0M | $878.0M | ||
| Q3 24 | $253.0M | $1.0B | ||
| Q2 24 | $115.0M | $1.0B | ||
| Q1 24 | $163.0M | $710.0M |
| Q4 25 | — | $607.0M | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $957.0M | ||
| Q1 25 | — | $423.0M | ||
| Q4 24 | — | $673.0M | ||
| Q3 24 | — | $829.0M | ||
| Q2 24 | — | $857.0M | ||
| Q1 24 | — | $543.0M |
| Q4 25 | — | 13.0% | ||
| Q3 25 | — | 24.2% | ||
| Q2 25 | — | 21.1% | ||
| Q1 25 | — | 10.2% | ||
| Q4 24 | — | 17.5% | ||
| Q3 24 | — | 20.4% | ||
| Q2 24 | — | 21.5% | ||
| Q1 24 | — | 13.7% |
| Q4 25 | — | 5.5% | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 5.6% | ||
| Q4 24 | — | 5.3% | ||
| Q3 24 | — | 5.2% | ||
| Q2 24 | — | 3.7% | ||
| Q1 24 | — | 4.2% |
| Q4 25 | — | 1.15× | ||
| Q3 25 | — | 2.14× | ||
| Q2 25 | 2.38× | 1.86× | ||
| Q1 25 | -1.53× | 50.23× | ||
| Q4 24 | — | 1.66× | ||
| Q3 24 | 1.81× | 3.78× | ||
| Q2 24 | — | 1.76× | ||
| Q1 24 | 4.41× | 1.31× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
TEL
| Automotive Industry End Market | $1.9B | 40% |
| Digital Data Networks | $707.0M | 15% |
| Automation And Connected Living Industry End Market | $549.0M | 12% |
| Energy Industry End Market | $406.0M | 9% |
| Aerospace Defense And Marine Industry End Market | $381.0M | 8% |
| Commercial Transportation Industry End Market | $370.0M | 8% |
| Sensors Industry End Market | $212.0M | 5% |
| Medical Industry End Market | $159.0M | 3% |
